Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Flow cytometric MRD detection in selected mature B-cell malignancies.

Böttcher S, Ritgen M, Kneba M.

Methods Mol Biol. 2013;971:149-74. doi: 10.1007/978-1-62703-269-8_9.

PMID:
23296963
2.

A comparison of the sensitivity of flow cytometry and bone marrow biopsy in the detection of minimal residual disease in chronic lymphocytic leukemia.

Maloum K, Charlotte F, Divine M, Cazin B, Lesty C, Merle-Béral H; French Cooperative Group on CLL.

Haematologica. 2006 Jun;91(6):860-1.

3.

Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation.

Böttcher S, Ritgen M, Pott C, Brüggemann M, Raff T, Stilgenbauer S, Döhner H, Dreger P, Kneba M.

Leukemia. 2004 Oct;18(10):1637-45.

PMID:
15343348
4.

Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice.

Stehlíková O, Chovancová J, Tichý B, Krejčí M, Brychtová Y, Panovská A, Francová Skuhrová H, Burčková K, Borský M, Loja T, Mayer J, Pospíšilová S, Doubek M.

Int J Lab Hematol. 2014 Apr;36(2):165-71. doi: 10.1111/ijlh.12149. Epub 2013 Sep 13.

PMID:
24028768
5.

Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.

Sánchez ML, Almeida J, Vidriales B, López-Berges MC, García-Marcos MA, Moro MJ, Corrales A, Calmuntia MJ, San Miguel JF, Orfao A.

Leukemia. 2002 Aug;16(8):1460-9.

6.

Minimal residual disease detection in mantle cell lymphoma: technical aspects and clinical relevance.

Pott C.

Semin Hematol. 2011 Jul;48(3):172-84. doi: 10.1053/j.seminhematol.2011.05.002. Review.

PMID:
21782059
7.

Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.

Böttcher S, Ritgen M, Buske S, Gesk S, Klapper W, Hoster E, Hiddemann W, Unterhalt M, Dreyling M, Siebert R, Kneba M, Pott C; EU MCL MRD Group.

Haematologica. 2008 Apr;93(4):551-9. doi: 10.3324/haematol.11267.

8.

MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR.

Pott C, Brüggemann M, Ritgen M, van der Velden VH, van Dongen JJ, Kneba M.

Methods Mol Biol. 2013;971:175-200. doi: 10.1007/978-1-62703-269-8_10.

PMID:
23296964
9.

Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis.

Böttcher S, Stilgenbauer S, Busch R, Brüggemann M, Raff T, Pott C, Fischer K, Fingerle-Rowson G, Döhner H, Hallek M, Kneba M, Ritgen M.

Leukemia. 2009 Nov;23(11):2007-17. doi: 10.1038/leu.2009.140. Epub 2009 Jul 30.

PMID:
19641522
10.

Detection of minimal residual disease in mantle cell lymphoma-establishment of novel eight-color flow cytometry approach.

Chovancová J, Bernard T, Stehlíková O, Šálek D, Janíková A, Mayer J, Doubek M.

Cytometry B Clin Cytom. 2015 Mar;88(2):92-100. doi: 10.1002/cyto.b.21210. Epub 2015 Jan 14.

PMID:
25586981
12.

Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol.

Noy A, Verma R, Glenn M, Maslak P, Rahman ZU, Keenan JR, Weiss M, Filippa D, Zelenetz AD.

Blood. 2001 Apr 1;97(7):1929-36.

13.

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.

Pott C, Hoster E, Delfau-Larue MH, Beldjord K, Böttcher S, Asnafi V, Plonquet A, Siebert R, Callet-Bauchu E, Andersen N, van Dongen JJ, Klapper W, Berger F, Ribrag V, van Hoof AL, Trneny M, Walewski J, Dreger P, Unterhalt M, Hiddemann W, Kneba M, Kluin-Nelemans HC, Hermine O, Macintyre E, Dreyling M.

Blood. 2010 Apr 22;115(16):3215-23. doi: 10.1182/blood-2009-06-230250. Epub 2009 Dec 23.

14.

Stem cell transplantation in poor-risk chronic lymphocytic leukemia: assessment of post-transplant minimal residual disease using four- and six-color flow cytometry and allele-specific RQ-PCR.

Itälä M, Huhtinen AR, Juvonen V, Kairisto V, Pelliniemi TT, Penttilä TL, Rauhala A, Tienhaara A, Remes K.

Eur J Haematol. 2008 Aug;81(2):100-6. doi: 10.1111/j.1600-0609.2008.01082.x. Epub 2008 Apr 10.

PMID:
18410542
15.

Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang.

Gimenez E, Chauvet M, Rabin L, Puteaud I, Duley S, Hamaidia S, Bruder J, Rolland-Neyret V, Le Gouill S, Tournilhac O, Voog E, Maisonneuve H, Jacob MC, Leroux D, Béné MC, Formisano-Tréziny C, Gabert J, Gressin R, Callanan MB.

Br J Haematol. 2012 Jul;158(2):186-97. doi: 10.1111/j.1365-2141.2012.09161.x. Epub 2012 May 25.

PMID:
22626453
16.

Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL.

Rawstron AC, Böttcher S, Letestu R, Villamor N, Fazi C, Kartsios H, de Tute RM, Shingles J, Ritgen M, Moreno C, Lin K, Pettitt AR, Kneba M, Montserrat E, Cymbalista F, Hallek M, Hillmen P, Ghia P; European Research Initiative in CLL.

Leukemia. 2013 Jan;27(1):142-9. doi: 10.1038/leu.2012.216. Epub 2012 Jul 31.

PMID:
23041722
17.

Analysis of CLLU1 expression levels before and after therapy in patients with chronic lymphocytic leukemia.

Buhl AM, James DF, Neuberg D, Jain S, Rassenti LZ, Kipps TJ.

Eur J Haematol. 2011 May;86(5):405-11. doi: 10.1111/j.1600-0609.2011.01588.x. Epub 2011 Mar 23.

18.
19.

Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia.

Moreno C, Villamor N, Colomer D, Esteve J, Giné E, Muntañola A, Campo E, Bosch F, Montserrat E.

Blood. 2006 Jun 1;107(11):4563-9. Epub 2006 Jan 31.

20.

Guess what: Chronic 13q14.3+/CD5-/CD23+ lymphocytic leukemia in blood and t(11;14)(q13;q32)+/CD5+/CD23- mantle cell lymphoma in lymph nodes!

Lima M, Pinto L, Dos Anjos Teixeira M, Canelhas A, Mota A, Cabeda JM, Silva C, Queirós ML, Fonseca S, Santos AH, Brochado P, Justiça B.

Cytometry B Clin Cytom. 2003 Jan;51(1):41-4.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk